Heart failure (HF) and chronic obstructive pulmonary disease (COPD) are chronic, progressive syndromes that share numerous risk factors and clinical symptoms. We sought to analyse the relationship between COPD status and outcomes in patients receiving empagliflozin or placebo in the EMPEROR-Preserved ...
the Effect of Dapagliflozin on the Incidence of Cardiovascular Events–Thrombolysis in Myocardial Infarction 58], respectively),6 confirmed the heart failure prevention benefits of SGLT2is as a class in a broader population of patients with and without established atherosclerotic cardiovascular disease. No...
The researchers found that the risk for first heart failure hospitalization and total heart failure hospitalizations was significantly lower in the empagliflozin group versus the placebo group during a median follow-up of 17.9 months (hazard ratio, 0.77 for first heart failure hospitalization; rate rati...
Introduction: Sodium-glucose co-transporter 2 inhibitors were initially used in the treatment of type 2 diabetes mellitus and subsequently, it was shown to be useful in heart failure among patients with or without diabetes mellitus. This study aimed to find out the prevalence of empagliflozin use ...
Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: the EMPEROR-Preserved trial. Circulation. 2022;145(3):184-193. doi:10.1161/CIRCULATIONAHA.121.057812 PubMedGoogle ScholarCrossref 7. Kelkar AA, Spertus J, Pang P...
and heart disease to lower the risk of death from heart attack or stroke. Empagliflozin works by increasing the removal of sugar by your kidneys.Empagliflozin is also used to treat heart failure and kidney disease. It helps to lower the risk of death from heart disease and reduces the need ...
Stimulation with ANG2 and GLUC increased atrial expression of both MAOs and oxidative stress; the effects were significantly decreased by the SGLT2i. Atrial oxidative stress positively correlated with the echocardiographic size of heart chambers and negatively with the left ventricular ejection fraction....
Empagliflozin is also used to lower the risk of death fromheart attack, stroke, orheart failurein adults with type 2 diabetes who also haveheart disease. Empagliflozin is also used in adults to lower the risk of dying or needing to be in a hospital for heart failure when the heart cannot...
官方标题 Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart Failure (EMPATHY) - a Phase III Trial. 时间视角 (Time Perspective) 盲法(masking) Quadruple(Care Provider,Outcomes Assessor,Investigator,Participant) 试验开始日期 2022-03-15 主要试验完成日期 2024-09-30 试验...
CHICAGO -- October 28, 2020 -- In patients with heart failure and a reduced ejection fraction, empagliflozin reduced serious heart failure and serious adverse kidney events, and slowed the decline in kidney function, regardless of the presence or absence of chronic kidney disease (CKD), according...